Melanoma Biomarkers
BRAF V600E — present in roughly half of all melanomas — is one of the most actionable mutations in oncology: BRAF + MEK inhibitor combinations can produce rapid, significant tumor shrinkage.
Reviewed by XpertPatient Medical Advisory · Updated June 2026 · Sources: NCI · ACS · ASCO · NIH/PMC
Start Here
What is a biomarker?
A biomarker in melanoma is usually a specific gene mutation found in your tumor. The most important one is called BRAF V600E. About half of all melanomas have this mutation — and there are powerful drugs designed specifically to block it.
Melanoma has been transformed by two types of treatment: targeted therapy for BRAF-mutated tumors, and immunotherapy that activates your immune system. Biomarker testing tells your doctor which path — or which combination — is right for you.
What this means for you: BRAF mutation status is the first thing tested in advanced melanoma. It determines whether targeted pills are an option, or whether immunotherapy is the primary approach.
The Tests Your Doctor Orders
🔍 Is there a mutation that drives rapid growth — and can be targeted?
Found in about 50% of melanomas. BRAF V600E causes a growth signal to get stuck ‘on.’ Targeted drug combinations like dabrafenib + trametinib block this signal and can shrink tumors quickly. For patients who need a fast response, this can be life-changing.
🔍 Is there a related mutation without a targeted drug yet?
Found in about 20% of melanomas. There’s no approved targeted drug for NRAS melanoma yet. Immunotherapy is the main treatment option, and MEK inhibitors are being studied in clinical trials.
🔍 Can immunotherapy help your immune system attack the cancer?
High PD-L1 is associated with better single-agent immunotherapy response — but even PD-L1-negative melanomas can respond to combination immunotherapy (nivolumab + ipilimumab), so PD-L1 alone doesn’t exclude you from immunotherapy.
Sources: Melanoma Research Foundation · NCI · ACS
Watch & Learn
Common Questions
Melanoma Biomarkers — Your Questions Answered
Should I choose targeted therapy or immunotherapy?
Both are valid options for BRAF-positive melanoma. Targeted therapy works faster — better if you need rapid tumor shrinkage. Immunotherapy tends to produce more durable, long-lasting remissions. Your oncologist will consider how fast the cancer is growing and your overall health.
What if I don’t have a BRAF mutation?
BRAF-negative melanoma is primarily treated with immunotherapy — pembrolizumab, nivolumab, or nivolumab + ipilimumab. NRAS-mutated melanoma may benefit from MEK inhibitors in clinical trials.
Can melanoma be cured with immunotherapy?
Yes, in some patients. Long-term data shows some patients — particularly those treated with combination immunotherapy — achieve very durable remissions that look like functional cures. This is one of the most exciting areas in cancer medicine.
What does PD-L1-negative mean?
It means lower PD-L1 expression on tumor cells. Single-agent immunotherapy has lower response rates in PD-L1-negative melanoma — but the combination of nivolumab + ipilimumab still works, regardless of PD-L1 status.
Know Your Biomarkers. Own Your Journey.
Free, survivor-led cancer education for newly diagnosed patients.
Visit the Melanoma Center → Full Biomarkers Guide →
